Methicillin-Resistant Staphylococcus Aureus Infection

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Methicillin-Resistant Staphylococcus Aureus Infection is an early-stage landscape with 3 programs across 1 company. The most active players are Hikma Pharmaceuticals LLC. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Hikma Pharmaceuticals LLC

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

Vancomycin

Hikma Pharmaceuticals LLC

Phase 1

No programs

Phase 2

No programs

Phase 31

Cotrimoxazole

University of California, San Francisco

Approved1

Povidone-Iodine

Becton, Dickinson and Company

Analysis

Trial Status

clinical trials

Completed3 · 100%

Clinical Trials

Trial Activity

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

Completed·SSavara Inc.·Phase 3·NCT03181932·188 enrolled

Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections

Completed·RRabin Medical Center·Phase 3·NCT00427076·252 enrolled

Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection

Completed·559th Medical Wing·N/A·NCT00822692·139 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)